Guangzhou Innogen Pharmaceutical Group Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

Why is Guangzhou Innogen Pharmaceutical Group Co., Ltd. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1,099.21%

EBIT Growth (5y)

25.42%

EBIT to Interest (avg)

-231.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.54

EV to EBIT

-5.13

EV to EBITDA

-5.29

EV to Capital Employed

835.76

EV to Sales

12.67

PEG Ratio

Dividend Yield

ROCE (Latest)

-16285.85%

ROE (Latest)

-29.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET SALES(HY)

Higher at HKD 82.18 MM

RAW MATERIAL COST(Y)

Fallen by -8,105% (YoY

-9What is not working for the Company

ROCE(HY)

Lowest at -36.73%

PRE-TAX PROFIT(Q)

At HKD -229.85 MM has Fallen at -163.43%

NET PROFIT(Q)

At HKD -229.85 MM has Fallen at -163.43%

INTEREST(Q)

Highest at HKD 1.41 MM

Here's what is working for Guangzhou Innogen Pharmaceutical Group Co., Ltd.

Net Sales

Higher at HKD 82.18 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (HKD MM)

Raw Material Cost

Fallen by -8,105% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

At HKD 6.41 MM has Grown at 44.79%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Guangzhou Innogen Pharmaceutical Group Co., Ltd.

Pre-Tax Profit

At HKD -229.85 MM has Fallen at -163.43%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -229.85 MM has Fallen at -163.43%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (HKD MM)

Interest

Highest at HKD 1.41 MM

in the last five periods and Increased by 209.83% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)